CoChat

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

Open access

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Abstract

Colorectal cancer is one of the world’s most prevalent and lethal cancers. Mutations of the KRAS gene occur in ~40% of metastatic colorectal cancers. While this cohort has historically been difficult to manage, the last few years have shown exponential growth in the development of selective inhibitors targeting KRAS mutations. Their foremost mechanism of action utilizes the Switch II binding pocket and Cys12 residue of GDP-bound KRAS proteins in G12C mutants, confining them to their inactive state. Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting. Other KRAS inhibitors in development include a multi-targeting KRAS-mutant drug and a G12D mutant drug. Treatment resistance remains an issue with combination treatment regimens including indirect pathway inhibition and immunotherapy providing possible ways to combat this. While KRAS-mutant selective therapy has come a long way, more work is required to make this an effective and viable option for patients with colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15082375

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RAS-mediated signaling pathway. Signaling begins with a ligand such as the epidermal growth factor (EGF) binding to a receptor tyrosine kinase such as the EGF receptor (EGFR). This binding activates downstream guanine nucleotide exchange factor (GEF) proteins such as the son of sevenless (SOS) protein to mediate cycling of GDP to GTP on RAS proteins. This cycling induces a conformational change that allows for binding with downstream signaling components. RAS once activated can bind RAF and signal through the mitogen-activated pathway kinase (MAPK) pathway or bind to phosphatidylinositol-3 kinase (PI3K) and signal through the PI3K pathway. The PI3K pathway can then activate or be activated by the mammalian target of rapamycin (mTOR) pathway. The downstream effect of these pathways leads to transcriptional reprogramming, affecting cellular survival, differentiation, apoptosis, and proliferation. The signaling of RAS is controlled by intrinsic GTPase activity that is catalyzed by a GTPase-activating protein (GAP) to hydrolyze the GTP into GDP and induce RAS into its inactive conformation.
Figure 1 RAS-mediated signaling pathway. Signaling begins with a ligand such as the epidermal growth factor (EGF) binding to a receptor tyrosine kinase such as the EGF receptor (EGFR). This binding activates downstream guanine nucleotide exchange factor (GEF) proteins such as the son of sevenless (SOS) protein to mediate cycling of GDP to GTP on RAS proteins. This cycling induces a conformational change that allows for binding with downstream signaling components. RAS once activated can bind RAF and signal through the mitogen-activated pathway kinase (MAPK) pathway or bind to phosphatidylinositol-3 kinase (PI3K) and signal through the PI3K pathway. The PI3K pathway can then activate or be activated by the mammalian target of rapamycin (mTOR) pathway. The downstream effect of these pathways leads to transcriptional reprogramming, affecting cellular survival, differentiation, apoptosis, and proliferation. The signaling of RAS is controlled by intrinsic GTPase activity that is catalyzed by a GTPase-activating protein (GAP) to hydrolyze the GTP into GDP and induce RAS into its inactive conformation.CC BY · PubMed Central
Figure 2 Direct inhibition of KRAS G12C mutation. The listed drugs Sotorasib, ASP2453, JDQ443, and Adagrasib work through a similar mechanism, binding to the mutated Cys12 residue of KRAS mutants. By making contacts with the Switch II pocket (SII-P) region, the inhibitors make a stable connection with KRAS and prevent structural change into its active conformation. Sotorasib uniquely binds to a His95 residue proximal to the SII-P to increase contact with the protein. In doing so, the inhibitors subdue tumorigenic phenotypes including cancer stemness, uncontrolled proliferation, and the ability to evade immune and drug attack. The series of inhibitors from Revolution Medicines, RMC-6291, RMC-6236, RMC-036, and RMC-037, bind instead to the GTP-bound active form of KRAS. Creating a tri-compound structure with Cyclophilin A, the inhibitors can bind G12C and other mutant KRAS proteins.
Figure 2 Direct inhibition of KRAS G12C mutation. The listed drugs Sotorasib, ASP2453, JDQ443, and Adagrasib work through a similar mechanism, binding to the mutated Cys12 residue of KRAS mutants. By making contacts with the Switch II pocket (SII-P) region, the inhibitors make a stable connection with KRAS and prevent structural change into its active conformation. Sotorasib uniquely binds to a His95 residue proximal to the SII-P to increase contact with the protein. In doing so, the inhibitors subdue tumorigenic phenotypes including cancer stemness, uncontrolled proliferation, and the ability to evade immune and drug attack. The series of inhibitors from Revolution Medicines, RMC-6291, RMC-6236, RMC-036, and RMC-037, bind instead to the GTP-bound active form of KRAS. Creating a tri-compound structure with Cyclophilin A, the inhibitors can bind G12C and other mutant KRAS proteins.CC BY · PubMed Central
Figure 3 Pan-pathway inhibition. The janus kinase/signal transducer and activator of transcription (JAK/STAT) and mitogen-activated protein kinase (MAPK) pathways are both activated by a tyrosine receptor kinase such as the epidermal growth factor receptor (EGFR). The EGFR once activated leads to autophosphorylation, which in turn activates JAK proteins. The STAT protein is then activated and can activate the cyclin-dependent kinase 4/6 (CDK4/6) proteins to affect cellular physiology. In the MAPK pathway, the EGFR activates the growth factor receptor-bound protein 2 (GRB2), which acts as an adapter protein to activate the son of sevenless (SOS) protein. SOS can directly facilitate the cycling of guanine diphosphate (GDP) on the rat sarcoma virus (RAS) protein for guanine triphosphate (GTP), inducing its active conformation. Active KRAS can continue signaling through the MAPK pathway by binding the rapidly accelerated fibrosarcoma (RAF) protein, or it can act bind phosphatidylinositol-3 kinase (PI3K) and promote signaling through this pathway. RAF can then bind the MAPK/ERK kinase (MEK), which can activate extracellular signal regulated kinase (ERK). In the PI3K pathway, phosphatidylinositol-dependent kinase 1 (PDK1) is activated, which activates protein kinase B (AKT). All three pathways are distinctly different but are interconnected; the inhibition at any of one these steps can easily be compensated and therefore requires multi-targeted inhibition for effect.
Figure 3 Pan-pathway inhibition. The janus kinase/signal transducer and activator of transcription (JAK/STAT) and mitogen-activated protein kinase (MAPK) pathways are both activated by a tyrosine receptor kinase such as the epidermal growth factor receptor (EGFR). The EGFR once activated leads to autophosphorylation, which in turn activates JAK proteins. The STAT protein is then activated and can activate the cyclin-dependent kinase 4/6 (CDK4/6) proteins to affect cellular physiology. In the MAPK pathway, the EGFR activates the growth factor receptor-bound protein 2 (GRB2), which acts as an adapter protein to activate the son of sevenless (SOS) protein. SOS can directly facilitate the cycling of guanine diphosphate (GDP) on the rat sarcoma virus (RAS) protein for guanine triphosphate (GTP), inducing its active conformation. Active KRAS can continue signaling through the MAPK pathway by binding the rapidly accelerated fibrosarcoma (RAF) protein, or it can act bind phosphatidylinositol-3 kinase (PI3K) and promote signaling through this pathway. RAF can then bind the MAPK/ERK kinase (MEK), which can activate extracellular signal regulated kinase (ERK). In the PI3K pathway, phosphatidylinositol-dependent kinase 1 (PDK1) is activated, which activates protein kinase B (AKT). All three pathways are distinctly different but are interconnected; the inhibition at any of one these steps can easily be compensated and therefore requires multi-targeted inhibition for effect.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 42

Metadata

Authors
Tria, S. M., Burge, M. E., & Whitehall, V. L. J.
Affiliations
  • QIMR Berghofer Medical Research Institute (AU)
  • The University of Queensland (AU)
  • Queensland Health (AU)
Corresponding author
  • Tria, Simon Manuel
  • Whitehall, Vicki L. J.
Venue
Cancers
Publisher
MDPI AG
Published
2023-04-19
Volume
15
Issue
8
Pages
2375
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4366549009
Cited by
38
References
91
Citations by year
2026: 8 · 2025: 18 · 2024: 10 · 2023: 2
FWCI
1.23
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Tour de Cure (RSP-248-18/19)
  • Garry Whyte Sea Angel PAF (RSP-248-18/19)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS mutation, metastatic colorectal cancer, KRAS G12C inhibitors, sotorasib, adagrasib, KRAS G12D, immunotherapy, treatment resistance, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. https://app.cochat.ai/papers/10.3390/cancers15082375
The paper
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023). The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Cancers. https://doi.org/10.3390/cancers15082375

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.